Govani Viraj, Shastry Adithya, Iosifescu Daniel, Govil Preetika, Mayer Megan, Sobeih Tarek, Choo Tse, Wall Melanie, Sehatpour Pejman, Kantrowitz Joshua
Nathan Kline Institute.
Department of Psychiatry, Columbia University.
Res Sq. 2023 May 19:rs.3.rs-2943290. doi: 10.21203/rs.3.rs-2943290/v1.
Auditory cognition is impaired in schizophrenia, and typically engages a complex, distributed, hierarchical network, including both auditory and frontal input. We recently demonstrated proof of principle for the target engagement of an N-methyl-D-aspartate-type glutamate receptor (NMDAR) agonist + auditory targeted remediation (d-serine+AudRem) combination, showing significant improvement in auditory-learning induced plasticity and mismatch negativity. In this secondary analysis, we report on frontal EEG outcomes, assessing for both generalized effects and the mechanism of auditory plasticity. 21 schizophrenia or schizoaffective disorder participants were randomized to three 1x weekly AudRem + double-blind d-serine (100 mg/kg) visits. In AudRem, participants indicated which paired tone was higher in pitch. The focus of this secondary analysis was a frontally (premotor) mediated EEG outcome- event-related desynchronization in the b band (b-ERD), which was shown to be sensitive to AudRem in previous studies. d-Serine+AudRem led to significant improvement in b-ERD power across the retention and motor preparation intervals (F =6.0, p=0.025) vs. AudRem alone. b-ERD was significantly related to baseline cognition, but not auditory-learning induced plasticity. The principal finding of this prespecified secondary analysis are that in addition to improving auditory based biomarkers, the d-serine+AudRem combination led to significant improvement in biomarkers thought to represent frontally mediated dysfunction, suggesting potential generalization of effects. Changes in auditory-learning induced plasticity were independent of these frontally mediated biomarkers. Ongoing work will assess whether d-serine+AudRem is sufficient to remediate cognition or whether targeting frontal NMDAR deficits with higher-level remediation may also be required. NCT03711500.
精神分裂症患者存在听觉认知障碍,其通常涉及一个复杂的、分布式的、分层的神经网络,包括听觉和额叶输入。我们最近证明了N-甲基-D-天冬氨酸型谷氨酸受体(NMDAR)激动剂+听觉靶向修复(d-丝氨酸+AudRem)组合的靶点参与的原理,显示出听觉学习诱导的可塑性和失配负波有显著改善。在这项二次分析中,我们报告额叶脑电图结果,评估其对听觉可塑性的一般影响和机制。21名精神分裂症或分裂情感性障碍参与者被随机分为三组,每组每周进行1次AudRem+双盲d-丝氨酸(100mg/kg)治疗。在AudRem治疗中,参与者指出哪对音调的音高更高。这项二次分析的重点是额叶(运动前区)介导的脑电图结果——b频段事件相关去同步化(b-ERD),在先前的研究中已证明其对AudRem敏感。与单独使用AudRem相比,d-丝氨酸+AudRem在保留和运动准备间隔期间导致b-ERD功率显著改善(F =6.0,p=0.025)。b-ERD与基线认知显著相关,但与听觉学习诱导的可塑性无关。这项预先指定的二次分析的主要发现是,除了改善基于听觉的生物标志物外,d-丝氨酸+AudRem组合还导致被认为代表额叶介导功能障碍的生物标志物有显著改善,表明效果可能具有普遍性。听觉学习诱导的可塑性变化与这些额叶介导的生物标志物无关。正在进行的工作将评估d-丝氨酸+AudRem是否足以改善认知,或者是否也需要通过更高水平的修复来靶向额叶NMDAR缺陷。临床试验注册号:NCT03711500。